Molybdenum is the trace mineral at the active site of four human enzymes: sulfite oxidase (the last step of sulfur amino-acid disposal), xanthine oxidase (uric-acid production), aldehyde oxidase, and mitochondrial amidoxime reductase — all carrying it in the molybdopterin cofactor. The requirement is the smallest of all mineral RDAs, 45 µg, met several times over by legumes, grains, and nuts; dietary deficiency has never been confirmed outside long-term parenteral nutrition without it, and the mineral's clinical fame is genetic: cofactor deficiency and isolated sulfite oxidase deficiency are devastating inborn errors. Its other claim is therapeutic antagonism — excess molybdenum induces copper deficiency, exploited in sheep and considered in Wilson's disease.
Class
Trace mineral (molybdate, MoVI)
Best Food Sources
Legumes, whole grains, nuts, dairy
Adult Daily Reference Intake
45 µg (50 in lactation); UL 2,000 µg
Deficiency
Not dietary in practice — genetic cofactor disease
Excess
Copper deficiency via antagonism (UL 2 mg)
Role in the Body
Sulfur disposal: sulfite oxidase turns sulfite into sulfate — the exit step for sulfur amino-acid metabolism; its genetic failure floods the brain with sulfite, causing seizures and lens dislocation in infancy.
Purine catabolism: xanthine oxidase's molybdenum cycles as it oxidises hypoxanthine to xanthine to uric acid — purine catabolism's last steps, see nucleic acids — the target of allopurinol, which mimics its substrate.
Detoxication: aldehyde oxidase clears nicotine metabolites and drug aldehydes, giving the cofactor a quiet role in pharmacokinetics.
Sources & Absorption
Molybdate absorbs efficiently (about 90%) in the small intestine; the kidney regulates total body balance, and urinary excretion tracks intake.
Legumes are the standout source (root nodules concentrate it), with grains and nuts behind; food content again follows soil.
Average intakes run 2–3 times the RDA in most populations — the safest margin of any trace mineral.
Deficiency & Toxicity
The single convincing human deficiency case-series came from long-term total parenteral nutrition lacking molybdenum: tachycardia, headache, night blindness, and sulphite-derived neurotoxicity, reversed by supplementation.
Molybdenum cofactor deficiency — the genetic disease — presents with intractable neonatal seizures; cPMP replacement therapy now treats the most common subtype.
The 2 mg ceiling is extrapolated from industrial-exposure and animal data showing copper antagonism, not from food.
Interactions
With copper: excess molybdenum binds copper in the gut (with sulfur) as an unavailable thiomolybdate — the basis of cattle's "teart" pasture disease and of experimental therapy in copper overload.
With sulfur metabolism: the sulfite oxidase link makes methionine and cysteine loads the metabolic context of the cofactor's work.
Allopurinol and febuxostat inhibit the molybdenum enzyme itself — pharmacology's daily encounter with the mineral.